Deutivacaftor

Deutivacaftor
Product Description

Deutivacaftor, also known as ivacaftor-d9, VX-561, or CTP-656, is a precision-deuterated analog of ivacaftor in which nine hydrogen atoms are replaced by deuterium. It is a CFTR potentiator that increases the probability of channel opening of CFTR proteins delivered to the cell surface. Deuteration slows drug clearance, resulting in a longer half-life compared to ivacaftor. It is used as a component of the triple combination with vanzacaftor and tezacaftor (Alyftrek®).

Read more Show less

Solarte

  • Country/Region:
    China
  • On CPHI since:
    2026
View company profile
Categories
more categories Show less
Specifications
  • CAS Registry Number
    1413431-07-8
More specifications Fewer specifications

Solarte

  • Country/Region:
    China
  • On CPHI since:
    2026
View company profile

More Products from Solarte (4)

  • Elexacaftor

    Product Elexacaftor

    Elexacaftor is a CFTR corrector that binds to the F508del-CFTR protein and stabilizes its conformation, thereby facilitating its processing and trafficking to the cell surface. When combined with tezacaftor and ivacaftor, elexacaftor and tezacaftor bind to different sites on the CFTR protein and have an ad...
  • Ivacaftor

    Product Ivacaftor

    Ivacaftor is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator. It binds directly to the CFTR protein at the cell surface and increases the open probability of the ion channel, thereby enhancing chloride transport across cell membranes. It is indicated for the treatment of cystic fib...
  • Tezacaftor

    Product Tezacaftor

    Tezacaftor is a CFTR corrector. It facilitates the cellular processing and trafficking of normal and select mutant forms of CFTR (including F508del-CFTR) to increase the amount of mature CFTR protein delivered to the cell surface, resulting in increased chloride transport. Tezacaftor is used in combination...
  • Vanzacaftor

    Product Vanzacaftor

    Vanzacaftor (VX-121) is a CFTR corrector for class II CFTR mutations, the most common being F508del. It improves the processing and trafficking of defective CFTR proteins, allowing them to reach the cell surface and function properly. Vanzacaftor is administered as part of a triple combination with tezacaf...